4D Molecular Therapeutics (FDMT) Retained Earnings (2019 - 2025)
Historic Retained Earnings for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to -$735.7 million.
- 4D Molecular Therapeutics' Retained Earnings fell 3972.79% to -$735.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$735.7 million, marking a year-over-year decrease of 3972.79%. This contributed to the annual value of -$576.2 million for FY2024, which is 3873.29% down from last year.
- Latest data reveals that 4D Molecular Therapeutics reported Retained Earnings of -$735.7 million as of Q3 2025, which was down 3972.79% from -$678.8 million recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Retained Earnings ranged from a high of -$152.1 million in Q1 2021 and a low of -$735.7 million during Q3 2025
- Its 5-year average for Retained Earnings is -$388.6 million, with a median of -$372.8 million in 2023.
- Per our database at Business Quant, 4D Molecular Therapeutics' Retained Earnings tumbled by 6369.44% in 2022 and then crashed by 2947.96% in 2024.
- 4D Molecular Therapeutics' Retained Earnings (Quarter) stood at -$207.0 million in 2021, then tumbled by 51.93% to -$314.5 million in 2022, then crashed by 32.06% to -$415.3 million in 2023, then crashed by 38.73% to -$576.2 million in 2024, then fell by 27.68% to -$735.7 million in 2025.
- Its last three reported values are -$735.7 million in Q3 2025, -$678.8 million for Q2 2025, and -$624.2 million during Q1 2025.